The Targeted Sequencing Services segmentation by application delineates five primary domains: Oncology, Rare Disease, Infectious Disease, Pharmacogenomics, and Agricultural Genomics. Oncology accounts for the largest share, driven by the demand for actionable mutation profiling in personalized cancer therapy, which contributes roughly 45 % of total market revenue. Rare disease applications, representing about 25 % of the market, are propelled by the need for precise variant detection in low-prevalence genetic disorders, often supported by orphan‑drug development incentives. Infectious disease sequencing, at 15 %, is linked to rapid pathogen identification and antimicrobial‑resistance monitoring, especially in outbreak contexts. Pharmacogenomics, comprising 10 % of the market, underpins drug‑response testing that informs dosage adjustments and adverse‑event mitigation. Finally, Agricultural Genomics, with a 5 % share, supports marker‑assisted breeding and trait selection in crops and livestock. Collectively, these application categories define the market’s revenue composition and guide strategic investment across the targeted sequencing services landscape.